Ascendis Pharma A/S
Ascendis Pharma is a global biopharmaceutical company that develops therapies using its TransCon technology platform. Its two marketed products, YORVIPATH and SKYTROFA, treat hypoparathyroidism and growth hormone deficiency, respectively. Its clinical-stage portfolio includes candidates in endocrinology rare disease and oncology, and it is also applying the platform to areas including metabolic and cardiovascular diseases and ophthalmology. TransCon technologies are designed to extend drug action through sustained release of active parent drugs. Ascendis Pharma commercializes approved products directly in the United States and in select European countries, and uses sales and distribution agreements and licensing partnerships to reach other markets. It also partners with companies to develop and commercialize products in specified territories and therapeutic areas. The company is headquartered in Hellerup, Denmark.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ASND in the last 30 days.
See all $ASND insider activity →Ascendis Pharma A/S (ASND) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 PRESS RELEASE Ascendis Pharma Reports Third Quarter 2026 Financial Results – Q3 2026 product revenue of € 366 million (+89% Y/Y), comprising € 291 million for YORVIPATH ® , € 59 million for SKYTROFA ® , and € 16 million for YUVIWEL ® – Received positive CHMP and COMP
Ascendis Pharma (ASND) reported Q3 2026 revenue of €370M, up 73% YoY, driven by YORVIPATH sales. Operating profit rose to €125M from €11M, and net profit reached €74M, reversing a prior-year loss. The company expects EU marketing authorization for TransCon CNP in Q4 2026 and plans its first EU launch in Germany in Q1 2027. Positive clinical data for TransCon CNP was also presented.
The EMA's COMP recommended maintaining orphan designation for Ascendis Pharma's TransCon CNP for achondroplasia in children. If approved by the European Commission, it would grant 10 years of market exclusivity. A final decision is expected in Q4 2026, following U.S. approval in February 2026.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning ASND (Ascendis Pharma A/S). Coverage has skewed bullish: 6 bullish, 0 neutral, and 0 bearish.
Recent ASND coverage spans regulation, earnings and technology.
Earnings beat and robust revenue growth suggest upside pressure on the stock.
Strong earnings beat and profit swing likely drive buying pressure.
The orphan designation opinion is a material regulatory milestone that could boost the stock.
Positive clinical outcomes for TransCon PTH suggest stronger market adoption and potential revenue uplift.
Positive catalyst for Ascendis' growth prospects.
AlphAI scores every news story that mentions ASND with an AI model for sentiment and relevance, and aggregates insider trades from Ascendis Pharma A/S's SEC EDGAR Form 4 filings. Figures refresh continuously.
Ascendis Pharma A/S (ASND) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 PRESS RELEASE Ascendis Pharma Reports Third Quarter 2026 Financial Results – Q3 2026 product revenue of € 366 million (+89% Y/Y), comprising € 291 million for YORVIPATH ® , € 59 million for SKYTROFA ® , and € 16 million for YUVIWEL ® – Received positive CHMP and COMP
Ascendis Pharma (ASND) reported Q3 2026 revenue of €370M, up 73% YoY, driven by YORVIPATH sales. Operating profit rose to €125M from €11M, and net profit reached €74M, reversing a prior-year loss. The company expects EU marketing authorization for TransCon CNP in Q4 2026 and plans its first EU launch in Germany in Q1 2027. Positive clinical data for TransCon CNP was also presented.
The EMA's COMP recommended maintaining orphan designation for Ascendis Pharma's TransCon CNP for achondroplasia in children. If approved by the European Commission, it would grant 10 years of market exclusivity. A final decision is expected in Q4 2026, following U.S. approval in February 2026.
Ascendis Pharma (ASND) reported clinical data showing sustained kidney function improvements in hypoparathyroidism patients treated with TransCon PTH. Pooled data from 139 patients showed mean eGFR increases of 7.2 and 9.6 mL/min/1.73 m² at 26 and 52 weeks. 68.9% and 49.6% of patients saw eGFR increases of at least 5 and 10 mL/min/1.73 m², respectively. ASND shares were up 0.68% at $245.21.
AstraZeneca withdrew its EU application for Truqap in prostate cancer. Orphelia Pharma gained CHMP backing for Kizfizo in glioblastoma. Ascendis Pharma neared EU approval for Yuviwel in achondroplasia. Sobi expanded Tryngolza's use to severe hypertriglyceridemia. Pfizer withdrew Ibrance's EU expansion. Revolution Medicines got CHMP backing for Rasonque in pancreatic cancer. Omeros failed to overturn Yartemlea's EU rejection. Lilly advanced Foundayo for obesity and diabetes in Europe.
Ascendis Pharma (ASND) received a positive European regulatory opinion for its achondroplasia drug, already FDA-approved as YUVIWEL. Final EU approval is expected in Q4 2026, with a potential Germany launch in Q1 2027. ASND shares closed down 0.6%, despite the positive opinion. The drug recorded €7.6–8 million in Q2 revenue, part of the company's €315 million total product revenue.
Ascendis Pharma (ASND) announced the EMA's CHMP recommended marketing authorization for TransCon CNP (navepegritide) to treat achondroplasia in children. The EU's final decision is expected in Q4 2026, with a potential launch in Germany in Q1 2027. The therapy was approved in the U.S. in February 2026.
Analysts from Barclays and J.P. Morgan maintained Buy ratings on Merck (MRK), Tarsus Pharmaceuticals (TARS), and Ascendis Pharma (ASND). MRK has a $150 PT from Barclays, $180 from Scotiabank. TARS has a $110 PT from Barclays, $116 from Goldman Sachs. ASND has a $318.31 avg PT. All stocks have upside potential according to analysts.
Ascendis Pharma (ASND) will present data at ASBMR 2026 showing normalization of bone mass in hypoparathyroidism patients treated with palopegteriparatide over five years. The company will also share updates on navepegritide for achondroplasia, including improved growth and physical functioning in children.
Ascendis Pharma (ASND) will present data on its hypoparathyroidism and achondroplasia programs at ASBMR 2026. Key updates include 5-year data from TransCon PTH trials showing normalized bone mass and microarchitecture. The company also plans to share results from its achondroplasia trials, including growth and physical function improvements.
